Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO $TBP.ca

Posted by AGORACOM-JC at 9:09 AM on Monday, July 24th, 2017

Tbp large new

  • Appointmented of Bernard Fortier to the position of Chief Executive Officer
  • Over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields

OTTAWA, ONTARIO–(July 24, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors. Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a Board member.

Bernard Fortier is a graduate from the MBA program at l’école des Hautes Études Commerciales (HEC) in Montreal, with over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields.

Mr. Fortier spent 5 years in the USA working in the therapy and rehabilitation market, having graduated from the physiotherapy program at Laval University. His experience in the USA enabled him to work on business development and management early in his career. After completing his MBA in 2001, he joined the pharmaceutical industry with a biotechnology company. He spent 8 years in various key commercial roles at Serono Canada (now EMD Serono) in the Multiple Sclerosis field, including National Sales Manager for the Neurology business unit.

In 2010, Bernard became the Country Manager for Nutricia Canada, the specialized medical nutrition division of Groupe Danone. He was recruited in 2012 to launch a new pharmaceutical company called Orimed Pharma. Through licensing deals and internal product development, the company’s portfolio grew from 3 to 10 products within 4 years.

“I am very pleased to welcome Bernard to the team as our new CEO as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Bernard is an experienced leader and executive with proven skills in leadership, strategy and execution, as well as business development and negotiation. Mr. Fortier has a clear mandate from the Board, to grow revenue and build Tetra as a global leader in pharmaceutical cannabis. Going forward, we will be placing considerable efforts in expanding Tetra in the U.S. market.”

Corporate Update:

Mr. Andre Rancourt, previous interim CEO was elected to the position as Chairman of the Board of Directors. The Board has mandated Mr. Rancourt to continue taking an active and dynamic role as he demonstrated as Interim CEO. Mr. Rancourt will be responsible for the administration, overall corporate governance and financing of the corporation.

Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a member of the Board. The Corporation wishes to thank Mr. Audet for all his efforts in working to grow Tetra where it is today and looks forward to his continued participation in building Tetra as a global leader in pharmaceutical cannabis.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
www.tetrabiopharma.com

Tetra Bio-Pharma Signs LOI with Constance Therapeutics TBP.ca

Posted by AGORACOM-JC at 9:52 AM on Wednesday, July 19th, 2017

Tbp large new

  • Signed a Letter of Intent (LOI) with Constance Therapeutics,
  • Clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products
  • AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market

OTTAWA, ONTARIO–(July 19, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.

The AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market under a commercial license agreement. “Over the coming months, the corporation will be focusing its energy on generating revenues while becoming an important player in the medical marijuana market,” commented Mr. Andre Rancourt, CEO of Tetra. “The products developed by Constance Therapeutics are exactly what the corporation is looking for in terms of novel cannabis products developed for patients. The approach used by Constance Therapeutics is exactly the type of business model that Tetra is implementing to bring medical marijuana products to patients.”

“Constance Therapeutics works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions, such as cancer, lyme, auto-immune, chronic pain, neurodegenerative diseases, and other out-of-option patients,” commented Constance Finley, Founder and CEO of Constance Therapeutics, Inc. She added, “over the years, research demonstrates that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls.”

Tetra will enter into a licensing agreement with Constance Therapeutics to perform clinical research on the novel cannabis extract products initially focusing on their use in treating patients with brain cancer. Tetra will work closely with oncologists to evaluate the therapeutic benefit of these products according to pharmaceutical standards.

These products are currently available to patients living in California, USA and are consumed sublingually and through vaporization. As part of its mission to bring effective cannabinoid-based products to cancer patients, Tetra will be working in partnership with Constance Therapeutics to investigate the potential efficacy in a clinical trial.

About Constance Therapeutics:

Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics’ products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420. For further information, visit: www.constancetherapeutics.com.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Marijuana Company of America Receives Financing for JV in Washington State $MCOA.us

Posted by AGORACOM-JC at 9:41 AM on Wednesday, July 19th, 2017

15233 mcoa

  • Contributed the first installment of capital to Bougainville Ventures, Inc. in partial satisfaction of the joint venture agreement entered into earlier this year in Washington State
  • MCOA received $375,000 in its first round of financing
  • Investment will contribute to funding the development of a state-of-the-art 30,000 sq. ft. greenhouse grow facility in Oroville, Washington

ESCONDIDO, CA–(Jul 19, 2017) – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative cannabis and hemp marketing and distribution Company, is pleased to announce that it has contributed the first installment of capital to Bougainville Ventures, Inc. (“BV”) in partial satisfaction of the joint venture agreement entered into earlier this year in Washington State.

MCOA received $375,000 in its first round of financing. This investment will contribute to funding the development of a state-of-the-art 30,000 sq. ft. greenhouse grow facility in Oroville, Washington. Once completed, the greenhouse facility will accommodate a cannabis production and processing tenant with a Tier 3, I-502 license with significant experience growing cannabis. The total principal amount of the convertible note that MCOA executed with its financing partner is $752,500, with a 16 month term and 10% annual interest rate. Additional rounds of financing will be received as part of this note, which MCOA intends to invest in BV in satisfaction of the terms of its JV agreement.

As turnkey landlords, MCOA and BV look to provide an ideal cultivation environment that their current tenant can move into in Q3, and be fully operational and revenue producing in early Q4. As more states legalize the cultivation and consumption of cannabis, MCOA intends to replicate this business model and build the Company’s real estate portfolio and increase its revenue.

Donald Steinberg, MCOA President and CEO, said, “I am very pleased that we obtained the financing to start our operations in Washington. We are projecting that this joint venture will soon be profitable and be a model that we can replicate in other states and countries. We are also happy to establish a relationship with a financing partner that is interested in supporting joint venture projects for MCOA in the future.”

The closing of its first round of financing is a significant step in completing the Company’s JV partnership that was formed to construct two greenhouses, provide management services and a commercial lease to an I-502 licensed grower in Washington State.

Separately, the Company announced effective July 1, 2017, the establishment of a new corporate office located at 1320 West Valley Parkway, Escondido, California, 92029, that will include space for the Company’s back office support team for its HempSMART brand, and provide office space for some Company executives.

ABOUT BOUGAINILLE VENTURES, INC.
Bougainville Venture Inc. is in the core business of converting irrigated farmland that was traditionally used to grow marginally profitable feed crops, to greenhouse-equipped farmland used to grow luxury crops with a primary focus on high-density and high-yielding crops. Bougainville is an agricultural services company that focuses on providing growers with state-of-the-art computer controlled greenhouses and processing facilities. Bougainville offers fully built out turnkey solutions to tenant-growers and provides growing infrastructure, as well as landlord services for licensed I-502 producers and processors in the state of Washington.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders’ Meeting & Provides a Corporate Update $TBP.ca

Posted by AGORACOM-JC at 5:30 PM on Tuesday, July 11th, 2017

Tbp large new

  • Tetra is the only pharmaceutical company to have clinical studies for smoked marijuana;
  • The Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline

OTTAWA, ONTARIO–(July 11, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders’ meeting.

Resolution For Against Withheld Spoiled No Vote % For % Against % Withheld
André Rancourt 18,439,319 0 19,449 0 443,314 99.89 % 0.00 % 0.11 %
André D. Audet 18,439,304 0 19,464 0 443,314 99.89 % 0.00 % 0.11 %
Robert Brouillette 18,456,735 0 2,033 0 443,314 99.99 % 0.00 % 0.01 %
Dr. W.M. (Bill) Cheliak 18,456,750 0 2,018 0 443,314 99.99 % 0.00 % 0.01 %
Appointment of McGovern, Hurley, Cunningham, LLP, as auditors of the Corporation and to authorize the directors to fix the remuneration to be paid to the auditors. 18,884,340 0 17,742 0 0 99.91 % 0.00 % 0.09 %
The amendment of the Stock Option Plan from fixed to rolling. 18,282,545 176,222 0 0 443,315 99.05 % 0.95 % 0.00 %

At the meeting, some key corporate highlights which were discussed, included:

  • Tetra is the only pharmaceutical company to have clinical studies for smoked marijuana;
  • The Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • The initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than what we expected for sales. We are now putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control. We will look at launching PPP001 using the ACMPR license by the end of summer. See press release announced April 17, 2017 for further information;
  • We are looking to start the Phase II clinical trials for PPP002 – Dronabinol XL in the next month; and
  • Investor outreach will be principally focused on the U.S. market going forward looking at targeting healthcare funds to potentially invest in Tetra. Communications strategy is to make very clear that Tetra is not a marijuana company but a pharmaceutical company.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals $TBP.ca

Posted by AGORACOM-JC at 9:05 AM on Wednesday, July 5th, 2017

Tbp large

  • Strengthened its position on bringing marijuana to patients in the form of a prescription drug
  • Has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017

OTTAWA, ONTARIO–(July 5, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug. Tetra has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017. According to this report, Tetra is the only company developing dried marijuana as a drug.

One in five Canadians will live with pain in their lifetime and one in two will be affected by cancer. Canadian courts have ruled in favor of patients wanting access to marijuana for relief. In response to these decisions, the Canadian government has implemented the Access to Cannabis for Medical Purposes Regulations (ACMPR) to help bring marijuana to patients. Canada’s Prime Minister has been very favorable in bringing marijuana to patients but it will be up to corporations to step in and adhere to the Canadian Food and Drug regulations to bring marijuana medications to patients. Tetra is a world leader in the drug development field of cannabis-based medications and is paving the road to become the first company to commercialize a dried marijuana product as a drug in North America.

“Canadian’s are entitled to access to marijuana to treat their pain or its co-morbidities. It is not a question of social standing or a judgement if the act of ‘smoking’ is acceptable for patients. It is a fundamental right to have access to a botanical drug that can effectively allow patients to have a better quality of life,” commented Dr. Guy Chamberland, CSO of Tetra Bio-Pharma. “There is sufficient evidence suggesting that smoking marijuana is an adequate medication to help relieve pain and improve a patient’s well-being. Both of these are important aspects to offering effective therapies to patients. The challenge has been addressing quality and safety issues to meet the standards of a drug.”

Over the years our society has inherited an image that ‘smoking’ or ‘vaporizing’ is not associated with a healthy approach to health care. According to the expert committee on the Health Effects of Marijuana (National Academies Press, 2017), ‘smoking cannabis does not increase the risk for certain cancers (i.e., lung, head and neck)’. In addition, cancer patients typically consume an amount of dried marijuana per day, in dry weight, that is less than 1 tobacco cigarette, without the paper, per day. The significantly reduced amount of smoke per day is one of the explanations supporting that smoking marijuana does not increase the risk for these cancers. That said, these are effective routes of delivering a complex botanical medication. “Society has to focus on caring for all patients living with pain not just those that want a different dosage form,” commented Dr. Chamberland. He added, “In fact our challenge is to characterize the safety and efficacy of this therapy, ensure lot-to-lot quality, provide adequate risk information to health professionals, demonstrate the safety and efficacy so that physicians can adequately assess the potential efficacy and safety for their patient, and actively pursue more tolerable dosage forms to offer these innovative cannabis therapies to patients. In the end, a patient’s desire to smoke marijuana for relief has to be defended by Canadian courts and politicians. We live in a democratic society and we have to care for everyone.”

“Tetra undertook the development of PPP001 as a first prescription marijuana drug. The company is preparing its phase 3 trial in cancer patients and will assess the safety and efficacy using both the titanium pipe and vaporizer delivery systems. From Day 1, Tetra was dedicated to characterizing the safety and tolerability of consuming medical marijuana by smoking. Tetra also adopted the firm position of working transparently with regulators because the corporation believed it is important to bring marijuana, as traditionally used, to patients. Tetra will continue to work with provincial and federal governments, including physician and pharmacist professional corporations, to help address issues associated with the development and commercialization of a first prescription medical marijuana drug.”

“Tetra already works closely with Health Canada through the regulatory processes in place for the development of drugs and controlled substances,” commented Dr. Chamberland. He added that, “Tetra was working closely with the province of New Brunswick whom from Day 1 was very active in preparing for the eventual legalization of marijuana in Canada. Tetra is working with physician and pharmacist professional associations/corporations and will be working closely with these health professionals as the company prepares for its Phase 3 trial and the eventual commercialization of the first dried marijuana drug.”

“Tetra has performed safety, pharmacokinetic and cognitive function studies in healthy volunteers. The corporation has characterized the safety of consuming marijuana and understands what the potential risks are to consumers and patients. This information will be made available by Tetra to Health Canada and to other government departments on request. We believe that this safety data provides a clear and accurate picture of what happens to people that smoke marijuana recreationally,” commented Dr. Chamberland. “We believe it is our responsibility to provide this information to regulators to help pave the road for the Trudeau government’s legalization.”

In addition, Tetra will use its clinical knowledge from its Phase 1 and Safety clinical studies to implement effective and secure patient care programs. This includes working with independent professional organizations to transfer its clinical risk information and ensure that these groups provide continued medical education to their health professionals. Dr. Chamberland commented, “Launching the first dried marijuana drug in Canada brings a responsibility of ensuring that all safety risks are communicated to health professionals to ensure the well-being of consumers. No body wants another fentanyl-type crisis; all we want is for patients to obtain relief and an improved quality of life when consuming marijuana that is of the same quality as any other prescription medication.”

“Tetra will be actively pursuing the development and commercialization of PPP001 to remain a world leader in the field of cannabis medicine,” commented Andre Rancourt, CEO of Tetra Bio-Pharma. “We are dedicated to working with distributors and pharmaceutical companies interested in bringing medical marijuana as a prescription drug around the world. We are focusing on bringing to patients what the Supreme Court of Canada ruled was their right: access to marijuana.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Expands Focus of Commercialization Activities into the Lucrative Veterinary Market $TPB.ca

Posted by AGORACOM-JC at 8:27 AM on Wednesday, June 28th, 2017

Tbp large

  • Commercializing novel cannabinoid based formulations for the treatment of pet conditions
  • Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities

OTTAWA, ONTARIO–(June 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment of pet conditions.

Over the last year, Tetra demonstrated its leadership in the development of human prescription cannabinoid drugs and will use the same strategy to become a leader in the field of veterinary cannabinoid drug products. Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities. In fact, Tetra is well suited to tackle the veterinary drug market since the ACMPR was created to allow human patient’s access to medical marijuana and does not provide any measures to allow testing of cannabis or cannabis derived products in pets.

According to a USA Federal Trade Commission May 2015 report, in 2014, Americans spent approximately $58 billion on their pets, including medications. This number more than doubled since 2001. This market is expected to enjoy excellent growth over the next decade as new therapies provide better and more tolerable treatment for pets. According to Andre Rancourt, CEO of Tetra Bio-Pharma, “After carefully studying the veterinary pet market and potential partnerships, the company decided to expand its development activities in order to tap into this lucrative market. In addition, Tetra is very fortunate to have Dr. Chamberland who has considerable experience navigating the regulatory affairs in the veterinary industry.”

Tetra had announced the successful completion of several corporate milestones associated with the development of its prescription drug products. These announcements lead to discussions with veterinary specialists who expressed the need for novel cannabinoid therapies for pets.

Tetra will create a Veterinary Advisory board consisting of veterinary specialists in the fields of ophthalmology, oncology and pain. This board of veterinary experts will help guide the development to ensure that the products target unmet veterinary needs for domestic animals. Tetra will use the veterinary drug development program to expand its potential revenues from the sales of a drug product in both the human and pet drug markets. The corporation will also establish partnerships with pharmaceutical companies specialized in the sale and distribution of veterinary products.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Appoints Aphria CFO, Mr. Carl Merton to the Board of Directors $TBP.ca

Posted by AGORACOM-JC at 9:00 AM on Wednesday, June 14th, 2017

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564502/hub/TBP_large.jpg

  • Appointed Mr. Carl A. Merton to the Board of Directors, effective immediately. 

OTTAWA, ONTARIO–(June 14, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has appointed Mr. Carl A. Merton to the Board of Directors, effective immediately.

Mr. Merton has over 20 years of financial and business experience, including 10 years experience as a CFO for public companies involved in the capital markets. Beginning with 12 years combined with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance functions. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. After assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In his role as CFO, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”). He holds a B.Comm. Hon. in Sports Administration from Laurentian University, and has served as a past Chair of both the CICBV and the International Association of Professional Business Valuators. Mr. Merton is currently a member of the Board of Directors and Chair of the Audit Committee of Motor City Community Credit Union.

“We are most pleased to welcome Mr. Merton to the board as we continue to work closely with our strategic partner, Aphria in building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman and CEO of Tetra Bio-Pharma. “Mr. Merton’s tremendous experience as a CFO of publicly listed companies has resulted in raising in excess of $200 million. His vast network both in the U.S. and Canada will be a key factor in the Company’s growth. We look forward to working closely with him in building Tetra as a global leader in pharmaceutical cannabis.”

About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(514) 360-8040 Ext. 20

Tetra Bio-Pharma Strengthens its Board with the Appointment of Dr. Bill Cheliak $TBP.ca

Posted by AGORACOM-JC at 4:13 PM on Tuesday, May 30th, 2017

Tbp large

  • Announced that it has appointed Dr. W.M. (Bill) Cheliak to the Board of Directors effective immediately
  • Dr. Cheliak is CEO of Panag Pharma, a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation
  • Over 20 years of experience as an entrepreneur having helped establish companies in a wide variety of life science fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services

OTTAWA, ONTARIO–(May 30, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has appointed Dr. W.M. (Bill) Cheliak to the Board of Directors effective immediately.

Dr. Cheliak is CEO of Panag Pharma, a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of experience as an entrepreneur having helped establish companies in a wide variety of life science fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services. He brings extensive deal making experience with the pharmaceutical industry. He currently serves as a Director for Solarvest (SVS). Dr. Cheliak is Vice Chair of the Government of Canada’s Networks Centres Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee.

“We are most pleased to welcome Dr. Cheliak to the board as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman and CEO of Tetra Bio-Pharma. “As Tetra is now completely focused on becoming a global leader in pharmaceutical cannabis, Dr. Cheliak’s strong pharmaceutical background, knowledge and extensive networks will support the Company in the execution of its business plan.”

About Tetra Bio Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(514) 360-8040 Ext. 203

Marijuana Company of America Announces the Filing of Form 10 Reg Statement with SEC + Apply for QB upgrade $MCOA.us

Posted by AGORACOM-JC at 11:16 AM on Tuesday, May 23rd, 2017

15233 mcoa

  • Filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission
  • Important step in helping the Company to raise the necessary capital to fund its projects and expand its operations, as well as provide more transparent and reliable information to investors
  • Company will apply to upgrade its trading tier with OTC Markets to the OTCQB

BONSALL, CA–(May 23, 2017) – MARIJUANA COMPANY OF AMERICA, INC (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp company, is pleased to announce that it has filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This is an important step in helping the Company to raise the necessary capital to fund its projects and expand its operations, as well as provide more transparent and reliable information to investors.

Once the registration statement becomes effective, the Company will apply to upgrade its trading tier with OTC Markets to the OTCQB. Upgrading to the OTCQB is an efficient way to raise the Company’s profile among the investor and broker dealer communities, access greater liquidity, and trade on an SEC-recognized market, removing many of the trading restrictions placed on Pink market securities. The Form 10 filing provides investors detailed and audited information about MCOA‘s operations, including an overview of the business strategies, risk factors and financial statements. This additional and reliable information will help our investors make a more educated investment decisions about the Company.

“Taking steps to become a fully reporting company is yet another way that we are distinguishing ourselves from most of the marijuana public companies that report under the Alternative Reporting Standards on the OTC Pink market,” said Donald Steinberg, CEO of MCOA. “MCOA experienced substantial growth in 2016 and we hope to continue this momentum throughout 2017 as well. Our Form 10 filing and ongoing SEC reporting disclosures through audited annual financial statements, auditor reviewed quarterly financial statements and all material events will provide additional transparency to our shareholders and the investment community on our performance as we grow.”

MCOA‘s Form 10 Registration Statement includes audited financial statements of the business, an overview of the markets and industries in which the Company will operate, details regarding the Company’s management, and competitive strengths, strategies and risk factors. A copy of the Form 10 is available at www.sec.gov under the name of Marijuana Company of America, Inc. Additionally, the Form 10 can be found on the Investors Relations portion of the Company’s website at www.marijuanacompanyofamerica.com

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

Marijuana Company of America, Inc Announces the Launch of New Website $MCOA.us

Posted by AGORACOM-JC at 8:52 AM on Thursday, May 18th, 2017

15233 mcoa

  • Launched its new corporate website; www.marijuanacompanyofamerica.com.
  • Provides shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans

BONSALL, CA–(May 18, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or “the Company”) (OTC PINK: MCOA), an innovative cannabis and industrial hemp corporation, is pleased to announce the launch of its new corporate website; www.marijuanacompanyofamerica.com.

The new website will provide our shareholders and prospective investors with helpful information to make educated investment decisions. As the Company continues to execute its strategic plans, this new site will be the central hub for information about MCOA and the rapidly emerging cannabis and hemp industry.

Since starting the process to become fully reporting and uplisting to a higher financial exchange, the OTCQB, the Company has been engaging with institutional investors and analyzing meaningful M&A opportunities in the cannabis and industrial hemp marketplaces. This new site will be a useful tool in providing investors with updates on these developments.

MCOA recently engaged Hill and DraKoln Media (“H&D”) to develop the new website and provide marketing and brand management support. MCOA looks forward to capitalizing on H&D’s ability to communicate clearly and concisely with investors and consumers alike. They will develop a strong and lasting presence for the Company’s brands. MCOA will take full advantage of H&D’s ability to reach audiences across a variety of demographics related to our industry and expand our reach into new territory.

“We are very happy to finally be launching our new corporate website. David Hill and the Hill & DraKoln group did a wonderful job on the new site and we look forward to them launching the comprehensive branding and marketing strategy they are developing for the Company,” said Mr. Steinberg, MCOA President & CEO.

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Contact:
Marijuana Company of America, Inc
Investor Relations
1+(888)-777-4362
IR@mcoa.club